Redwood City, California and Dubai: Guardant360, the leading comprehensive liquid biopsy testing, will be available to more oncologists and their cancer patients in the Middle East through a distribution agreement between Guardant Health and IPS Genomix, the companies announced.
“We believe the great promise of Guardant360 is its ability to democratize access to critical information about a patient’s cancer,” said Helmy Eltoukhy, Guardant Health’s co-founder and CEO. “Now oncologists across the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman, Lebanon, Egypt and Jordan will have access to the same comprehensive information about the genomics of their patients’ solid tumors as doctors at the leading U.S. cancer centers through a single blood draw.”
Guardant360 is the first and most validated comprehensive liquid biopsy available commercially. It provides comprehensive analysis of all major classes of somatic tumor alterations. The test interrogates 70 cancer genes from a simple blood draw, with near-perfect specificity and high sensitivity. Using Guardant Health’s proprietary Digital Sequencing technology, Guardant360 can detect cell-free DNA at mutant allele fractions (MAF) as low as 0.1%, and will help match patients to targeted therapies and access precision care through a simple blood test
IPS Genomix will handle distribution, reimbursement, and will facilitate patient access for Guardant360 in The United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman, Lebanon, Egypt and Jordan. Guardant Health will perform all testing at its CLIA-certified and CAP-accredited laboratory in Redwood City, Calif.
“With more than 25 years of experience bringing world-class medical products to doctors in the Middle East and Africa, we aim to provide patients with the most effective and appropriate tools in fighting cancer.” said Ahmed Yacout, Chairman and CEO of IPS Group. “We are excited to help Guardant Health in this region through our dedicated personalized medicine expert teams in the region and expect oncologists here will rapidly adopt this exciting new technology.”
About Guardant Health:
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics, and cancer diagnostics. The company has raised $200 million from leading venture capital firms and its first product, Guardant360, came to market in 2014. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.
About IPS Genomix:
IPS Genomix was founded in 2013 by a group of experts who have been in the healthcare domain for more than 25 years in the Middle East and Africa territory. IPS Genomix partners with US and European molecular diagnostic companies, to provide a diversification of genomic testing services focused on improving patient care utilizing the latest technologies of prognostic, predictive & personalized medicine. The treating physician can then individualize the treatment of his patients to enhance the prevention and/or treatment of certain conditions and diseases. Given the rapid evolution of this particular field, IPS Genomix constantly incorporates new technology platforms and assays to offer physicians and their patients with the most up to date, reliable and cutting edge personalized medicine tools.